PDL BioPharma — Q2 2017 Earnings Presentation
14 slides from PDL BioPharma's earnings presentation, Aug 3, 2017
Slide 1: Second Quarter 2017 Financial Results Conference Call
PDL Second Quarter 2017 Financial Results Conference Call August 3, 2017
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua
Slide 3: Building Value Through Investments
Building Value Through Investments o Focused on growth in order to continue value creation for shareholders. o Have completed two significant equity transactions since last summer—Noden Pharma and LENSAR. o Built rich portfolio of income generating assets from which we are reaping the benefits—espec
Slide 4: Noden Background
Noden Background o Noden Pharma = Domiciled in Ireland and has operating companies in US and EU. = Platform upon which to build a specialty pharmaceutical company. = PDL purchased remaining interest in Noden in May 2017 and now owns 100% of Noden companies. = Noden already has two products on the ma
Slide 5: Commercializing Tekturna - US
Commercializing Tekturna - US o Transitioned responsibilities from Novartis to Noden in US and continuing the transition ex-US. o US net revenue increased 33% for Q2 to $12.9 million from $9.7 million in Q1. First full quarter utilizing contracted sales force. o Strategic imperative for Noden in the
Slide 6: Commercializing Rasilez — Ex US
Commercializing Rasilez — Ex US o Novartis distributing until transfer of marketing authorizations and Noden receiving a transfer of profits. = Transfers (specifically EU, Switzerland, Canada and Japan) are now expected to take place in the fourth quarter of this year. o Noden’s Q2 ex-US revenue inc
Slide 7: LENSAR - wholly owned subsidiary of PDL
LENSAR - wholly owned subsidiary of PDL o On May 11, LENSAR and PDL announced the financial restructuring of LENSAR. » LENSAR is now a wholly owned subsidiary of PDL. » Most of LENSAR outstanding debt owed to PDL was converted to equity. » PDL has begun to consolidate LENSAR’s financial statements e
Slide 8: Royalty & Debt Investments
16 Royalty & Debt Investments Royalty Acquisition [ kybella $9,500,000 July 2016 Royalty Acquisition ‘Senior Secured $85,000,000 September2015 Royalty Acquisition $85,600,000 November2014 Royalty Acquisition $15,500,000 ‘June 2014 ‘Senior Secured Note kaléo 150,000,000 ‘April 2044 Royalty Transactio
Slide 9: Building Value Through Investments
Building Value Through Investments PDL’s book value eased to $5.24 dend June 30, 2017 PDL's Book Value Per Share $5.50 5.25 5.00 $4.75 $4.50 $4.25 $4.00 $3.75 $3.50 $3.25 $3.00 $2.75 2.50 2.25 $2.00 S175 $1.50 $1.25 $1.00 $0.75 $0.50 $0.25 $0.00 2 Does not include asset value of royalties from Queen
Slide 10: Emphasizing PDL Value to Wall Street
10 Emphasizing PDL Value to Wall Street o New corporate website communicates PDL’s strategy, value and opportunity to multiple audiences. PDL st teins ene tin tt tot @: ©
Slide 11: Second Quarter 2017 Financials
Second Quarter 2017 Financials Three Months Ended Six Months Ended June 30, June 30, (In thousands, except per share amounts) (unaudited) 2017 2016 2017 2016 Royaties from Queen et al. patents S 16,285 _§ 14232 $ 30.441 _$ 135,687 Royalty rights - change in fair value 83,725 (855) 96,871 (27.957) In
Slide 12: Second Quarter 2017 Financials
Second Quarter 2017 Financials Condensed consolidated balance sheet (unaudited) June 30, December 31, 2017 2016 Cash, cash equivalents and investments $ 435,323 $ 242,141 Total notes receivable $ 217,193 $ 270,950 Total royalty rights - at fair value $ 342,958 $ 402,318 Total assets $ 1,301,971 $ 1,
Slide 13: PDL Share Repurchase Program
PDL Share Repurchase Program o On March 1, 2017, PDL’s board authorized the repurchase of issued and outstanding PDL common stock having an aggregate value of up to $30 million through March 2018. o As of June 30", completed the $30.0 million repurchase program. » Repurchased a total of 13.3 million
Slide 14: Question and Answer Session
PDL Question and Answer Session